Trials / Recruiting
RecruitingNCT07298005
Sonlicromanol in Post-COVID
SON4PEM Study: Sonlicromanol in Post-COVID: A Randomized, Double-blind, Placebo-controlled, Phase II Trial
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Michele van Vugt · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this randomized, double-blind, placebo-controlled, phase II trial, is to study the effect of sonlicromanol on fatigue in patients with post-COVID who experience post-exertional malaise (PEM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sonlicromanol | Sonlicromanol 90mg twice daily for 13 weeks |
| DRUG | Placebo | Placebo twice daily for 13 weeks |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2027-02-01
- Completion
- 2027-03-01
- First posted
- 2025-12-22
- Last updated
- 2026-04-13
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT07298005. Inclusion in this directory is not an endorsement.